This company has been acquired
Chembio Diagnostics Past Earnings Performance
Past criteria checks 0/6
Key information
-34.2%
Earnings growth rate
-19.5%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 14.6% |
| Return on equity | -130.9% |
| Net Margin | -47.0% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Chembio gets $3.2M contract from CDC to develop rapid test for syphilis
Sep 06Chembio stock rises 13% amid plans to develop rapid test for monkeypox
Aug 16Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt In A Risky Way?
Nov 30
Analysts' Revenue Estimates For Chembio Diagnostics, Inc. (NASDAQ:CEMI) Are Surging Higher
Aug 08Does Chembio Diagnostics (NASDAQ:CEMI) Have A Healthy Balance Sheet?
Jul 22Chembio Diagnostics EPS beats by $0.10, beats on revenue
May 06Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt Sensibly?
Apr 07Is Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Shareholder Ownership Skewed Towards Insiders?
Jan 16Chembio stock gains after COVID-19 tests nab European Union nod
Jan 14Is Chembio Diagnostics (NASDAQ:CEMI) Weighed On By Its Debt Load?
Dec 12
Chembio slumps 13% on delay of U.S. nod for coronavirus antibody test
Dec 04Chembio nabs BARDA contract for rapid respiratory antigen panel test
Dec 02Revenue & Expenses Breakdown
How Chembio Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 50 | -23 | 24 | 0 |
| 30 Sep 22 | 60 | -36 | 25 | 0 |
| 30 Jun 22 | 61 | -36 | 25 | -2 |
| 31 Mar 22 | 58 | -38 | 26 | 0 |
| 31 Dec 21 | 48 | -34 | 25 | 0 |
| 30 Sep 21 | 37 | -27 | 25 | 0 |
| 30 Jun 21 | 36 | -26 | 25 | 6 |
| 31 Mar 21 | 34 | -25 | 23 | 0 |
| 31 Dec 20 | 32 | -26 | 21 | 0 |
| 30 Sep 20 | 29 | -22 | 17 | 0 |
| 30 Jun 20 | 28 | -21 | 16 | 0 |
| 31 Mar 20 | 33 | -16 | 16 | 0 |
| 31 Dec 19 | 34 | -14 | 16 | 0 |
| 30 Sep 19 | 35 | -13 | 16 | 0 |
| 30 Jun 19 | 37 | -11 | 14 | 0 |
| 31 Mar 19 | 35 | -10 | 13 | 0 |
| 31 Dec 18 | 35 | -8 | 11 | 0 |
| 30 Sep 18 | 33 | -7 | 10 | 0 |
| 30 Jun 18 | 30 | -5 | 9 | 0 |
| 31 Mar 18 | 25 | -5 | 9 | 0 |
| 31 Dec 17 | 24 | -6 | 9 | 0 |
| 30 Sep 17 | 22 | -7 | 9 | -6 |
| 30 Jun 17 | 18 | -8 | 9 | -4 |
| 31 Mar 17 | 18 | -15 | 8 | -2 |
| 31 Dec 16 | 18 | -13 | 8 | 0 |
| 30 Sep 16 | 18 | -11 | 7 | 8 |
| 30 Jun 16 | 21 | -10 | 7 | 7 |
Quality Earnings: CEMI is currently unprofitable.
Growing Profit Margin: CEMI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CEMI is unprofitable, and losses have increased over the past 5 years at a rate of 34.2% per year.
Accelerating Growth: Unable to compare CEMI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CEMI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-5.5%).
Return on Equity
High ROE: CEMI has a negative Return on Equity (-130.86%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/27 02:20 |
| End of Day Share Price | 2023/04/27 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chembio Diagnostics, Inc. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Raymond Myers | Benchmark Company |
| Mark Massaro | Canaccord Genuity |